SK Biopharmaceuticals Co., Ltd.
326030
Rankning i aktier
#4039
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Aktiekurs
$51.65
Marknadsvärde
$4.05B
Förändring (1 dag)
0.27%
Förändring (1 år)
-30.95%
Land
KR
Handel SK Biopharmaceuticals Co., Ltd. (326030)
Kategori
Healthcare
Historik för aktiesplit för SK Biopharmaceuticals Co., Ltd. (326030)
Aktien SK Biopharmaceuticals Co., Ltd. (symbol: 326030) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En 326030-aktie köpt före Oct 21, 2026 motsvarar nu 0 326030-aktier.
Den senaste spliten skedde den Oct 21, 2026.
En 326030-aktie köpt före Oct 21, 2026 motsvarar nu 0 326030-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
NL
|
|
| 0 | - |
CH
|
